USSTOCK.TODAY
Regular Market
Log in Sign up

Amgen and Vertex Pharmaceuticals: Economies of Scale and Steady Revenue Growth

The Motley Fool +1 · ·by G4L

VRTX Vertex Pharmaceuticals Inc
$547.09 +0.85%
View chart & analysis →
  1. 1Amgen is projected to record approximately $37.8 billion in revenue, a roughly 3% increase in 2026.
  2. 2Vertex Pharmaceuticals' revenue is expected to rise by approximately 10% to reach $13.3 billion in fiscal year 2026.
  3. 3Annual peak sales for forbetacicept are expected to be between $4 billion and $7 billion upon IgAN, pMN, and gMG approval.

So what's the key point?

Revenue for Amgen and Vertex Pharmaceuticals is expected to grow by about 3% and 10% respectively in 2026. There is anticipation for even higher earnings if new drugs receive approval.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

Vertex Pharmaceuticals Q3 revenue increased, but earnings per share missed expectations Earnings Whispers +1 · 6d agoVertex Pharmaceuticals Q3 Revenue Up 12% · Annual Guidance Raised The Motley Fool +1 · 6d agoSpaceX records $4.4 billion in Q3 net profit including investment gains from The Boring Company The Motley Fool +1 · Oct 24
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news